At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Apr 10, 2026 at 16:09 ET
Mesoblast received FDA clearance to proceed directly into a registrational trial for Ryoncil® (remestemcel-L-rknd) in Duchenne muscular dystrophy (DMD), a rare and fatal muscle-wasting disease affecting ~15,000 children in the U.S. The Phase 3 trial will enroll 76 patients aged 5–9, with primary endpoint of time-to-stand at nine months.
- FDA granted IND clearance for a registrational trial of Ryoncil® in Duchenne muscular dystrophy (DMD).
- Trial will enroll 76 pediatric patients (ages 5–9), randomized to Ryoncil® or placebo, with time-to-stand at 9 months as the primary endpoint.
- Ryoncil® is already FDA-approved for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children, supporting its safety profile.
- Mesoblast is partnering with Parent Project Muscular Dystrophy (PPMD) and the Duchenne Registry for patient identification and trial awareness.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access